CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Lapatinib

拉帕替尼 杂质对照品Lapatinib Impurities

32 个杂质条目32 impurity entries

本页汇总 拉帕替尼 的 32 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 32 impurity reference standards of Lapatinib. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 拉帕替尼(Lapatinib)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesThe Analytical Method Development for Genotoxic Impurities of Lapatinib Ditosylate Monohydrate by Reversed Phase High-Performance Liquid Chromatography
    Journal of chromatographic science · 2025 · Shah S et al.  ·  PMID 41396825  ·  DOI
  2. 杂质研究Impurity studiesDevelopment and Validation of Rapid Stability-Indicating RP-HPLC-DAD Method for the Quantification of Lapatinib and Mass Spectrometry Analysis of Degraded Products
    Journal of chromatographic science · 2015 · Saadat E et al.  ·  PMID 25491314  ·  DOI
  3. 分析方法Analytical MethodsDevelopment and Validation of Chemometrics-Assisted Green UPLC-MS/MS Bioanalytical Method for Simultaneous Estimation of Capecitabine and Lapatinib in Rat Plasma
    Journal of chromatographic science · 2022 · Alrobaian M et al.  ·  PMID 34318311  ·  DOI
  4. 分析方法Analytical MethodsBioanalytical Method Development and Validation of Doxorubicin and Lapatinib in Rat Plasma Using UHPLC-HESI-LTQ-MS
    Journal of chromatographic science · 2025 · Moinuddin SK et al.  ·  PMID 38088022  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisEGFR blocker lapatinib inhibits the synthesis of matrix metalloproteinases from synovial fibroblasts
    Turkish journal of medical sciences · 2022 · Kehribar DY et al.  ·  PMID 36326383  ·  DOI

拉帕替尼 —— 原料药与杂质对照品Lapatinib — drug substance & impurities

共 33 个条目(含原料药本体)33 items incl. the drug substance
Lapatinib structure
原料药 APIAPI
拉帕替尼Lapatinib
Lapatinib
CAS No.231277-92-2
Chemical FormulaC29H26ClFN4O4S
Purity>95%询价On request
10mg25mg50mg100mg
Lapatinib Ditosylate Monohydrate structure
—
二对甲苯磺酸拉帕替尼一水合物Lapatinib Ditosylate Monohydrate
Lapatinib Ditosylate Monohydrate
CAS No.388082-78-8
Chemical FormulaC29H26ClFN4O4S·2(C7H8O3S)·H2O
Purity>95%询价On request
10mg25mg50mg100mg
Lapatinib Impurity 2 structure
2
拉帕替尼杂质2Lapatinib Impurity 2
Lapatinib Impurity 2
CAS No.1807733-95-4
Chemical FormulaC29H24ClFN4O4S
Purity>95%询价On request
10mg25mg50mg100mg
Lapatinib Impurity 3 structure
3
拉帕替尼杂质3Lapatinib Impurity 3
Lapatinib Impurity 3
CAS No.697299-82-4
Chemical FormulaC26H20ClFN4O2
Purity>95%询价On request
10mg25mg50mg100mg
Lapatinib Impurity 4 structure
4
拉帕替尼杂质4Lapatinib Impurity 4
Lapatinib Impurity 4
CAS No.746591-42-4
Chemical FormulaC26H18FN3O3
Purity>95%询价On request
10mg25mg50mg100mg
Lapatinib Impurity 5 structure
5
拉帕替尼杂质5Lapatinib Impurity 5
Lapatinib Impurity 5
CAS No.1630985-13-5
Chemical FormulaC47H30Cl2F2N6O4
Purity>95%询价On request
10mg25mg50mg100mg
Lapatinib Impurity 6 structure
6
拉帕替尼杂质6Lapatinib Impurity 6
Lapatinib Impurity 6
CAS No.1152131-73-1
Chemical FormulaC26H17ClFN3O4
Purity>95%询价On request
10mg25mg50mg100mg
Lapatinib Impurity 7 structure
7
拉帕替尼杂质7Lapatinib Impurity 7
Lapatinib Impurity 7
CAS No.1360431-86-2
Chemical FormulaC29H26ClFN4O5S
Purity>95%询价On request
10mg25mg50mg100mg
Lapatinib Impurity 8 structure
8
拉帕替尼杂质8Lapatinib Impurity 8
Lapatinib Impurity 8
CAS No.2172855-57-9
Chemical FormulaC55H43Cl2F2N7O6S
Purity>95%询价On request
10mg25mg50mg100mg
Lapatinib Impurity 9 structure
9
拉帕替尼杂质9Lapatinib Impurity 9
Lapatinib Impurity 9
CAS No.1026818-86-9
Chemical FormulaC29H26ClFN4O4S
Purity>95%询价On request
10mg25mg50mg100mg
Lapatinib Impurity 10 structure
10
拉帕替尼杂质10Lapatinib Impurity 10
Lapatinib Impurity 10
CAS No.1393112-45-2
Chemical FormulaC29H26ClFN4O4S
Purity>95%询价On request
10mg25mg50mg100mg
Lapatinib Impurity 11 structure
11
拉帕替尼杂质11Lapatinib Impurity 11
Lapatinib Impurity 11
CAS No.231278-05-0
Chemical FormulaC29H28N4O4S
Purity>95%询价On request
10mg25mg50mg100mg
Lapatinib Impurity 12 structure
12
拉帕替尼杂质12Lapatinib Impurity 12
Lapatinib Impurity 12
CAS No.231277-91-1
Chemical FormulaC29H27ClN4O4S
Purity>95%询价On request
10mg25mg50mg100mg
Lapatinib Impurity 13 structure
13
拉帕替尼杂质13Lapatinib Impurity 13
Lapatinib Impurity 13
CAS No.633370-23-7
Chemical FormulaC29H27FN4O4S
Purity>95%询价On request
10mg25mg50mg100mg
Lapatinib Impurity 14 structure
14
拉帕替尼杂质14Lapatinib Impurity 14
Lapatinib Impurity 14
CAS No.1393112-44-1
Chemical FormulaC26H17ClFN3O3
Purity>95%询价On request
10mg25mg50mg100mg
Lapatinib Impurity 15 structure
15
拉帕替尼杂质15Lapatinib Impurity 15
Lapatinib Impurity 15
CAS No.231278-83-4
Chemical FormulaC26H18ClN3O3
Purity>95%询价On request
10mg25mg50mg100mg
Lapatinib Impurity 16 structure
16
拉帕替尼杂质16Lapatinib Impurity 16
Lapatinib Impurity 16
CAS No.202196-46-1
Chemical FormulaC26H19N3O3
Purity>95%询价On request
10mg25mg50mg100mg
Lapatinib Impurity 18 structure
18
拉帕替尼杂质18Lapatinib Impurity 18
Lapatinib Impurity 18
CAS No.320337-48-2
Chemical FormulaC26H19ClFN3O3
Purity>95%询价On request
10mg25mg50mg100mg
Lapatinib Impurity 19 structure
19
拉帕替尼杂质19Lapatinib Impurity 19
Lapatinib Impurity 19
CAS No.231278-84-5
Chemical FormulaC26H17ClFN3O3
Purity>95%询价On request
10mg25mg50mg100mg
Lapatinib Impurity 20 structure
20
拉帕替尼杂质20Lapatinib Impurity 20
Lapatinib Impurity 20
CAS No.1268997-70-1
Chemical FormulaC22H21ClN4O4S
Purity>95%询价On request
10mg25mg50mg100mg
Lapatinib Impurity 22 structure
22
拉帕替尼杂质22Lapatinib Impurity 22
Lapatinib Impurity 22
CAS No.202197-26-0
Chemical FormulaC13H11ClFNO
Purity>95%询价On request
10mg25mg50mg100mg
Lapatinib Impurity 23 structure
23
拉帕替尼杂质23Lapatinib Impurity 23
Lapatinib Impurity 23
CAS No.231278-20-9
Chemical FormulaC21H14ClFIN3O
Purity>95%询价On request
10mg25mg50mg100mg
Lapatinib Impurity 24 structure
24
拉帕替尼杂质24Lapatinib Impurity 24
Lapatinib Impurity 24
CAS No.1227853-06-6
Chemical FormulaC29H24ClFN4O4S
Purity>95%询价On request
10mg25mg50mg100mg
Lapatinib Impurity 25 structure
25
拉帕替尼杂质25Lapatinib Impurity 25
Lapatinib Impurity 25
CAS No.202197-25-9
Chemical FormulaC13H12FNO
Purity>95%询价On request
10mg25mg50mg100mg
Lapatinib Impurity 26 structure
26
拉帕替尼杂质26Lapatinib Impurity 26
Lapatinib Impurity 26
CAS No.59404-86-3
Chemical FormulaC13H12ClNO
Purity>95%询价On request
10mg25mg50mg100mg
Lapatinib Impurity 27 structure
27
拉帕替尼杂质27Lapatinib Impurity 27
Lapatinib Impurity 27
CAS No.6373-46-2
Chemical FormulaC13H13NO
Purity>95%询价On request
10mg25mg50mg100mg
Lapatinib Impurity 28 structure
28
拉帕替尼杂质28Lapatinib Impurity 28
Lapatinib Impurity 28
CAS No.179246-45-8
Chemical FormulaC13H11ClFNO
Purity>95%询价On request
10mg25mg50mg100mg
Lapatinib Impurity 29 structure
29
拉帕替尼杂质29Lapatinib Impurity 29
Lapatinib Impurity 29
CAS No.231278-25-4
Chemical FormulaC21H15FIN3O
Purity>95%询价On request
10mg25mg50mg100mg
Lapatinib Impurity 30 structure
30
拉帕替尼杂质30Lapatinib Impurity 30
Lapatinib Impurity 30
CAS No.320337-46-0
Chemical FormulaC21H15ClIN3O
Purity>95%询价On request
10mg25mg50mg100mg
Lapatinib Impurity 31 structure
31
拉帕替尼杂质31Lapatinib Impurity 31
Lapatinib Impurity 31
CAS No.202198-16-1
Chemical FormulaC21H16IN3O
Purity>95%询价On request
10mg25mg50mg100mg
Lapatinib Impurity 32 structure
32
拉帕替尼杂质32Lapatinib Impurity 32
Lapatinib Impurity 32
CAS No.1393175-04-6
Chemical FormulaC21H14ClFIN3O
Purity>95%询价On request
10mg25mg50mg100mg
Lapatinib Impurity 33 structure
33
拉帕替尼杂质33Lapatinib Impurity 33
Lapatinib Impurity 33
CAS No.202197-27-1
Chemical FormulaC13H11ClFNO
Purity>95%询价On request
10mg25mg50mg100mg
Lapatinib Impurity 35 structure
35
拉帕替尼杂质35Lapatinib Impurity 35
Lapatinib Impurity 35
CAS No.1356391-95-1
Chemical FormulaC26H17ClFN3O3
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

拉帕替尼 —— 研究文献与合成路线Lapatinib — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 拉帕替尼 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Lapatinib. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Development and Validation of Rapid Stability-Indicating RP-HPLC-DAD Method for the Quantification of Lapatinib and Mass Spectrometry Analysis of Degraded Products
    Saadat E, Dehghan Kelishady P, Ravar F, et al. · Journal of chromatographic science · 2015 · 被引 9cited 9
  2. Sideroflexin-1 promotes progression and sensitivity to lapatinib in triple-negative breast cancer by inhibiting TOLLIP-mediated autophagic degradation of CIP2A
    Andriani L, Ling YX, Yang SY, et al. · Cancer letters · 2024 · 被引 15cited 15
  3. Ligand-Directed Photodegradation of Interacting Proteins: Oxidative HER2/HER3 Heterodimer Degradation with a Lapatinib-Derived Photosensitizer
    Qiu J, Liu Q, Li P, et al. · Journal of medicinal chemistry · 2023 · 被引 11cited 11
  4. The Analytical Method Development for Genotoxic Impurities of Lapatinib Ditosylate Monohydrate by Reversed Phase High-Performance Liquid Chromatography
    Shah S, Savalia V, Vekariya H · Journal of chromatographic science · 2025
  5. A Validated RP-HPLC Method for the Estimation of Lapatinib in Tablet Dosage form using Gemcitabine Hydrochloride as an Internal Standard
    Kumar KK, Nagoji KE, Nadh RV · Indian journal of pharmaceutical sciences · 2012 · 被引 8cited 8

合成与制备工艺专利Synthesis & process patents

  1. PROCESS AND INTERMEDIATES FOR PREPARING LAPATINIB
    CHEN YUNG-FA, HENSCHKE JULIAN PAUL, LIU YUANLIAN, CHU GUODONG, et al. · 公开号 WO2011116634WO2011116634 · 2011
  2. POLYMORPHIC FORMS OF LAPATINIB DITOSYLATE AND PROCESSES FOR THEIR PREPARATION
    ZETINA-ROCHA CARLOS, CAMMISA EDUARDO GUSTAVO, WEERATUNGA GAMINI · 公开号 WO2011130831WO2011130831 · 2011
  3. NEW PREPARATION METHOD OF LAPATINIB
    WANG JINGYI, LIN DONG, LENG CHUANXIN, ZHANG JIN, et al. · 公开号 WO2011160594WO2011160594 · 2011
  4. Process for preparing lapatinib synthetic intermediate
    FEI LI, WUWEI WANG, XING JI, GUANHONG XU, et al. · 公开号 CN101575319CN101575319 · 2009
  5. FORMS OF LAPATINIB COMPOUNDS AND PROCESSES FOR THE PREPARATION THEREOF
    METSGER LEONID, MITTELMAN ARIEL, YURKOVSKI SLAVIK · 公开号 US2010087459US2010087459 · 2010

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

拉帕替尼 杂质谱研究要点Lapatinib — impurity profiling notes

下面这些是拿到 拉帕替尼 的 33 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 33 impurity entries for Lapatinib, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances